Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue Kidney International Année : 2021

Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy

Résumé

In this issue of Kidney International, the initial experience regarding the immunogenicity of prior coronavirus disease 2019 (COVID-19) infection and the response to the COVID-19 vaccines among patients on maintenance dialysis and kidney transplant recipients is summarized. Preliminary data suggest that there is durability of immune response after COVID-19 infection. Although immune response to the first dose of vaccine is less in infection-naïve patients than healthy individuals in both groups, after the second vaccine dose a significant portion of patients receiving maintenance dialysis develop robust antibody titers, whereas kidney transplant recipients show a less-strong immune response.

Dates et versions

hal-03915991 , version 1 (30-12-2022)

Identifiants

Citer

T. Alp Ikizler, P. Toby Coates, Brad Rovin, Pierre Ronco. Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. Kidney International, 2021, 99 (6), pp.1275-1279. ⟨10.1016/j.kint.2021.04.007⟩. ⟨hal-03915991⟩
10 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More